ELVN Enliven Therapeutics Forecast, Technical & Fundamental Analysis
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics... Show more
ELVN is expected to report earnings to rise 4.08% to -39 cents per share on August 19
Q2'26
Est.
$-0.40
Q1'26
Beat
by $0.06
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.18
Q2'25
Beat
by $0.06
The last earnings report on May 07 showed earnings per share of -37 cents, beating the estimate of -44 cents. With 453.39K shares outstanding, the current market capitalization sits at 3.56B.
A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with MLTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then MLTX could also see price increases.
ELVN in upward trend: price rose above 50-day moving average on June 12, 2026
ELVN moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend. In of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 12, 2026. You may want to consider a long position or call options on ELVN as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ELVN just turned positive on June 12, 2026. Looking at past instances where ELVN's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for ELVN crossed bullishly above the 50-day moving average on June 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELVN advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ELVN broke above its upper Bollinger Band on June 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ELVN entered a downward trend on June 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ELVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.241) is normal, around the industry mean (21.001). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ELVN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (368.009).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
